Acellular pertussis vaccines protect against disease butfail to prevent infection and transmission ina nonhuman primate model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 2, 2014, Pages 787-792

  Warfel, Jason M ^a   Zimmerman, Lindsey I ^a   Merkel, Tod J ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adaptive immunity; Animal models; IL 17; T cell memory; Whooping cough

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; TRIPLE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BABOON; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; LEUKOCYTOSIS; MEMORY T LYMPHOCYTE; NONHUMAN; PERTUSSIS; PRIMATE MODEL; PRIORITY JOURNAL; PROVOCATION TEST; SECONDARY INFECTION; SYMPTOMATOLOGY; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION;

ADAPTIVE IMMUNITY; ANIMAL MODELS; IL-17; T-CELL MEMORY; WHOOPING COUGH;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, BACTERIAL; COLONY COUNT, MICROBIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; LEUKOCYTES, MONONUCLEAR; PAPIO; UNITED STATES; WHOOPING COUGH;

EID: 84892564719     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314688110     Document Type: Article

References (54)

1. Mattoo S, Cherry JD (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18(2):326-382.
2. Heininger U (2010) Update on pertussis in children. Expert Rev Anti Infect Ther 8(2): 163-173.
3. Cherry JD, Heininger U (2009) Pertussis and other Bordetella infections. Textbook of Pediatric Infectious Diseases, eds Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (W.B. Saunders, Philadelphia), pp 1683-1706.
4. Centers for Disease Control and Prevention (CDC) (2012) National, state, and local area vaccination coverage among children aged 19-35 months?United States, 2011. MMWR Morb Mortal Wkly Rep 61:689-696.
5. CDC (2012) Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 61(52):ND-719-ND-732.
6. Hozbor D, et al. (2009) Pertussis epidemiology in Argentina: Trends over 2004-2007. J Infect 59(4):225-231.
7. Quinn HE, McIntyre PB (2007) Pertussis epidemiology in Australia over the decade 1995-2005-trends by region and age group. Commun Dis Intell 31(2):205-215.
8. Jackson DW, Rohani P (2013) Perplexities of pertussis: Recent global epidemiological trends and their potential causes. Epidemiol Infect, available at http://dx.doi.org/10.1017/S0950268812003093.
9. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group (2005) Resurgence of pertussis in Europe. Pediatr Infect Dis J 24(9):761-765.
10. Cherry JD (2012) Epidemic pertussis in 2012?the resurgence of a vaccine-preventable disease. N Engl J Med 367(9):785-787.
11. Clark TA, Messonnier NE, Hadler SC (2012) Pertussis control: Time for something new? Trends Microbiol 20(5):211-213.
12. Zhang L, Prietsch SO, Axelsson I, Halperin SA (2012) Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 3:CD001478.
13. Higgs R, Higgins SC, Ross PJ, Mills KH (2012) Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 5(5):485-500.
14. Friedrich MJ (2011) Research aims to boost pertussis control. JAMA 306(1):27-29.
15. Poland GA (2012) Pertussis outbreaks and pertussis vaccines: New insights, new concerns, new recommendations? Vaccine 30(49):6957-6959.
16. Elahi S, Holmstrom J, Gerdts V (2007) The benefits of using diverse animal models for studying pertussis. Trends Microbiol 15(10):462-468.
17. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ (2012) Nonhuman primate model of pertussis. Infect Immun 80(4):1530-1536.
18. Warfel JM, Beren J, Merkel TJ (2012) Airborne transmission of Bordetella pertussis. J Infect Dis 206(6):902-906.
19. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ (2013) Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 56(9):1248-1254.
20. Liko J, Robison SG, Cieslak PR (2013) Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 368(6):581-582.
21. Sheridan SL, Ware RS, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308(5):454-456.
22. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R (2013) Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 131(6):e1716-1722.
23. Rowlands HE, et al. (2010) Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 126(4):e816-e827.
24. Kolls JK, Khader SA (2010) The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 21(6):443-448.
25. Wei S, Zhao E, Kryczek I, Zou W (2012) Th17 cells have stem cell-like features and promote long-term immunity. OncoImmunology 1(4):516-519.
26. Pitcher CJ, et al. (2002) Development and homeostasis of T cell memory in rhesus macaque. J Immunol 168(1):29-43.
27. Libster R, Edwards KM (2012) Re-emergence of pertussis: What are the solutions? Expert Rev Vaccines 11(11):1331-1346.
28. Greco D, et al.; Progetto Pertosse Working Group (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl JMed 334(6):341-348.
29. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334(6):349-355.
30. Misegades LK, et al. (2012) Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 308(20):2126-2132.
31. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R (2012) Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367(11): 1012-1019.
32. Tartof SY, et al. (2013) Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131(4):e1047-e1052.
33. Witt MA, Katz PH, Witt DJ (2012) Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 54(12):1730-1735.
34. Deen JL, et al. (1995) Household contact study of Bordetella pertussis infections. Clin Infect Dis 21(5):1211-1219.
35. Heininger U, KleemannWJ, Cherry JD, Group SIDSS; Sudden Infant Death Syndrome Study Group (2004)A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics 114(1):e9-e15.
36. Warfel JM, Merkel TJ (2013) Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 6(4):787-796.
37. Andreasen C, Powell DA, Carbonetti NH (2009) Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS ONE 4(9):e7079.
38. Zhang X, et al. (2011) Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun 79(1):527-541.
39. Fennelly NK, et al. (2008) Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun 76(3):1257-1266.
40. Zhang X, Goel T, Goodfield LL, Muse SJ, Harvill ET (2011) Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol 186(8): 4895-4904.
41. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: Role of IL-17-producing T cells. J Immunol 177(11):7980-7989.
42. Ross PJ, et al. (2013) Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: Towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9(4):e1003264.
43. Schure RM, et al. (2012) T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin Vaccine Immunol 19(11):1879-1886.
44. Schure RM, et al. (2012) Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS ONE 7(7):e41928.
45. S?rensen CH, Larsen PL (1988) IgD in nasopharyngeal secretions and tonsils from otitis-prone children. Clin Exp Immunol 73(1):149-154.
46. Pabst O (2012) New concepts in the generation and functions of IgA. Nat Rev Immunol 12(12):821-832.
47. Perry DL, Bollinger L, White GL (2012) The Baboon (Papio spp.) as a model of human Ebola virus infection. Viruses 4(10):2400-2416.
48. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
49. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A (1997) Vaccine- and antigendependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 65(6):2168-2174.
50. Lai FY, et al. (2012) Comparative seroepidemiology of pertussis, diphtheria and poliovirus antibodies in Singapore: Waning pertussis immunity in a highly immunized population and the need for adolescent booster doses. Vaccine 30(24):3566-3571.
51. Castagnini LA, et al. (2012) Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis 54(1):78-84.
52. Nilsson L, Lepp T, von Segebaden K, Hallander H, Gustafsson L (2012) Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: Analyses of 10 years of pertussis surveillance. Vaccine 30(21):3239-3247.
53. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.
54. Meade BD, et al. (1995) Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96(3 Pt 2):570-575.